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SELECTIVE SUPPRESSION OF 
AUTOANTIBODY RESPONSES IN 
NZB/NZW MICE TREATED WITH 
LONG-TERM CYCLOPHOSPHAMIDE 
SARA ELLEN WALKER and GILES G. BOLE, JR. 
Autoimmune responses were assayed in 80 cyclo- 
phosphamide-treated and control NZB/NZW mice 
over a period of 1 year. Fluctuation between posi- 
tive and negative immunofluorescent heterogeneous 
ANA tests and daily alterations of ANA titers were 
detected i n  young mice of both sexes. Although high- 
dose cyclophosphamide therapy (8 mg/kg/day) failed 
to prevent the spontaneous appearance of ANA, 
titered ANA values were partially suppressed in high- 
dose treated mice. This study permitted sequential 
comparisons between ANA titers and anti-DNA as 
useful indices of cyclophosphamide-induced suppres- 
sion of autoimmune disease. ANA titers were ,rela- 
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tively resistant to cyclophosphamide therapy. Anti- 
bodies directed specifically against DNA were s u p  
pressed in mice receiving high-dose cyclophospha- 
mide. In  treated animals, decreased anti-DNA levels 
were associated with protection from severe glomeru- 
lonephritis and renal vasculitis. Treatment with low- 
dose cyclophosphamide (1 mg/kg/day) appeared para- 
doxically to stimulate autoantibody production and 
renal disease/vasculitis. 
Evolution of autoimmune disease in hybrid 
New Zealand Black/New Zealand White (NZB/NZW) 
mice is characterized by the spontaneous appearance 
of autoantibodies and immune complex glomerulone- 
phritis (1). Therapeutic studies have demonstrated 
that selected immunosuppressive drugs effectively 
modify the course of disease in these animals. In  1966 
Russell and coworkers (2) reported suppression of 
renal disease and prolongation of life in female NZB/ 
NZW mice treated with the alkylating agent cyclo- 
phosphamide. Other studies have shown that the 
therapeutic benefits of cyclophosphamide noted in 
NZB/NZW mice were associated with decreased num- 
bers of positive immunofluorescent tests for anti- 
nuclear antibodies (ANA) (3), and with delay in ap- 
pearance of antibodies directed specifically against de- 
oxyribonucleic acid (anti-DNA) (4). This evidence has 
supported the use of cyclophosphamide in treating 
patients with systemic lupus erythematosus (5).  
This report describes the effects of prolonged 
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therapy with high (8 mg/kg/day) a n d  low (1 mg/kg/ 
day) doses of cyclophosphamide on autoantibody for- 
mation and  renal disease in hybrid New Zealand mice. 
These animals were treated with cyclophosphamide 
until death. The incidence of neoplasms was 94y0 in 
high-dose treated mice, 21y0 in low-dose treated mice, 
a n d  9% in control mice (6). Aberrations in  autoanti- 
body responses detected i n  terminal sera collected 
from mice dying with lymphoreticular neoplasms will 
be described in  another report (7). 
Unexpectedly, variation between positive and 
negative tests for ANA i n  individual animals was com- 
mon in young mice of both sexes. T h i s  variability 
persisted in older control male mice a n d  high-dose 
treated females a n d  males. Although therapy with 
cyclophosphamide failed to  prevent the spontaneous 
appearance of positive tests for heterogeneous ANA, 
titered ANA values were partially suppressed in high- 
dose treated mice. Assays for anti-DNA showed that 
this antibody was decreased significantly after pro- 
longed treatment with high-dose cyclophosphamide. 
In mice treated with low-dose cyclophosphamide the 
incidence of ANA, elevated ANA titers, a n d  anti- 
DNA rose steadily over the 52-week period of obser- 
vation. Paradoxically, low-dose therapy appeared to 
accelerate autoimmune disease i n  hybrid New Zealand 
mice. 
MATERIALS AND METHODS 
Animals. Breeding pairs of New Zealand Black (NZB) 
and New Zealand White (NZW) mice were obtained from 
Mr. W.D. Hall, the University of Otago, Dunedin, New 
Zealand. Each colony is maintained by brother-sister matings 
Treatment Protocol. Eighty littermate female and 
male NZB/NZW mice aged 4 to 24 weeks were assigned 
at random to treatment and control groups. Weighed ali- 
quots of cydophosphamide (Cytoxan, Mead Johnson and 
Co, Evansville, Indiana) were dissolved in sterile 0.15 M 
NaCl immediately before administration. Each dose was 
injected in 0.1 ml volume into interscapular subcutaneous 
tissue of each mouse. Two doses were employed: 10 females 
and 10 males received daily injections of high-dose cyclo- 
phosphamide (8 mg/kg/day), and 10 females and 10 males 
were given low-dose cyclophosphamide (1 mg/kg/day). 
Twenty female control mice and 20 male controls received 
daily injections of 0.1 ml sterile 0.15 M NaC1. 
All mice were bled from the orbital plexus before 
injections started, and after 8, 24, and 52 weeks of treat- 
ment. Moribund mice were bled, killed, and autopsied. 
After 93 weeks, 5 surviving mice, aged 100 to 103 weeks, 
were killed to end the experiment. Blood was collected 
in plain capillary tubes and allowed to clot at room tem- 
(6). 
Table 1. Fluctuation Between Positive and Negative Tests 
for A N A  in Serial Examinations of Sera from 




Female mice 946 4 (1-7)t 
947 1 (7) 
948 3 (1-3) 
955 1 (3) 
956 3 (1) 
Male mice 950 3 (3) 
942 2 (3) 
943 4 (1-3) 
954 4 (1-3) 
- 
Total 16 
951 3 (1-3) 
944 6 (1-5) 
949 5 (1-3) - 
Total 23 
- 
*Each mouse was bled on alternate days for a period of 2 weeks. 
Seven samples of sera from each animal were tested. 
+Number of positive tests. Parentheses enclose highest tube num- 
ber ranges (I-log, of serum dilution) giving a positive test for 
ANA detected by an indirect immunofluorescent technique. 
perature. After centrifugation, serum was separated and 
stored in sealed capillary tubes without preservatives at 
-20°C. This serum was used for ANA and anti-DNA tests. 
Immunofluorescent Tests for ANA. The indirect 
immunofluorescent procedure described by Friou (8) and 
adapted for use in this laboratory (9) was used to test 
thawed mouse sera for heterogeneous ANA on human 
leukocyte substrate. Fluorescein-conjugated goat anti-mouse 
7s y-globulin (Hyland Laboratories, Costa Mesa, California) 
was employed. This antiserum was characterized by a molar 
F/P ratio of 3.8 and a protein concentration of 18.4 mg/ml 
(10). Antiserum was diluted 1:20 before use. Each sample 
of mouse serum was tested undiluted (1:l) and after addi- 
tion of phosphate-buffered saline (pH 7.0) at dilutions of 
1:4, 1:16, 1:64, 1:256, and 1:1024. In fourteen instances, 
sera diluted 1:1024 gave positive tests. These samples were 
diluted to 1:2048, and after repeated testing each serum 
at this dilution was ANA-negative. Each tube of diluted 
serum was given a number corresponding to 1-log, of the 
dilution. Therefore, undiluted serum (1: 1) was designated 
1, 1:4 = 3, 1:16 = 5, etc. Results were expressed as the 
highest tube number giving a positive test for ANA. 
Three patterns of nuclear fluorescence were identi- 
fied in positive tests: rim, homogeneous, and speckled. The 
typical appearance of each pattern on human white blood 
cell substrate has been described in another report from 
this laboratory (9). In many instances more than one pat- 
tern was found in individual nuclei on a single slide. This 
phenomenon was termed a “mixed” pattern. 
Day-to-day fluctuation between positive and nega- 
tive immunofluorescent ANA tests was studied in a separate 
group of 12 young NZB/NZW mice (Table 1). To test 
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Table 2. Characterization of KB Cell-derived 
“C-labeled DNA Used in Anti-DNA Determinations 
Mean 
Nitrocellulose Filter* Studies (counts/min) 
1. Control-0.6 M TCA precipitation 2636 
2. Test RNA contamination (IS) 
RNAaset incubation 2612 
NaOH hydrolysis 3005 
3. Test DNA purity-DNAaseS incubation 328 




2 X SSC! filtration (14) 
0.5 M NaCl filtration (15) 
S, nucleasel I incubation (16) 
Specific activity: 0.06 &i/Pg (1 1,600 counts/min/pg). Counting 
efficiency: 88y0. 
Spectrophotometric characterization (13). 260:280 mp ratio = 1.9; 
260:230 m@ ratio = 2.1. 
Protein contamination. not detected by Lowry test (17). 
*Each test utilized 0.26 fig (0.005 ml) l’c-labeled KB cell-derived 
DNA, and type B-6 (0.45 a) nitrocellulose filters, Schleicher and 
Schuell Inc. Keene, New Hampshire. 
tRibonuclease A, boiled, Worthington Biochemical Corp. Free- 
hold. New Jersey. 
SDeoxyribonuclease I (Bovine pancreas), P-L Biochemicals Inc, 
Milwaukee, Wisconsin. 
§One liter 2 X  SSC contains NaCI, 17.5 g, and Na citrate, 8.8 g. 
IlThis enzyme degraded specifically 920/, of denatured DNA in 
this test system. Experiments described in this table indicated 
that > 95% of l’c-labeled DNA used in anti-DNA determina- 
tions was double-stranded. 
the reproducibility of titered ANA determinations, pooled 
ANA-positive serum from untreated 12-month-old female 
NZB/NZW mice was divided into aliquots and frozen. This  
serum was tested repeatedly on 6 successive days. 
Anti-DNA Tests. KB cells of human tumor origin 
(11) grown in spinner culture (900 ml, 200,000 cells/ml) 
were exposed to 250 PCi thymidine-2-14C (specific activity 
54.1 Ci/mm) (New England Nuclear Corp, Boston, Massa- 
chusetts) a t  37°C for 72 hours. 14C-labeled DNA was separ- 
ated from the cells by phenol extraction using the method 
described by Pincus et a1 (12). T h e  concentration of re- 
covered DNA was calculated by assuming a n  optical den- 
sity of 1.0 at  260 mp for a solution containing 50 pg 
DNA/ml. Spectrophotometric, chemical, and enzymatic 
characterizations of the radioactive DNA preparation are 
listed i n  Table  2. 
DNA-binding tests were performed using a modifi- 
cation of the Farr technique described by Steinberg et a1 
(18). Optimal antigen-antibody concentrations used i n  anti- 
DNA tests were determined initially by setting up titration 
curves to study the effects of increasing volumes of mouse 
sera or %-labeled DNA on the binding reaction. Serum 
was heated a t  56°C for 60 minutes to decrease nonspecific 
binding. A serum aliquot of 0.015 ml and  0.034 pg labeled 
DNA (400 counts/minute) were employed i n  each test. 
After incubation at 37°C and  4°C. addition of saturated 
(NH4),S0,, and centrifugation, supernate and dissolved 
precipitate were applied separately to I-inch squares of 
Whatman 3-mm filter paper. Each dried paper was placed 
i n  20 ml of toluene scintillation fluid. and counted 10 
minutes in  a Packard Liquid Scintillation Counter. Per- 
cent binding was calculated using the formula: 
100 x 
precipitate counts/minute 
precipitate counts/minute + supernate counts/minute 
Renal Histology. Renal tissue obtained a t  autopsy 
was fixed, embedded, and stained as described i n  a previous 
report (6). Glomerular lesions i n  4-p sections of renal tissue 
were counted as described earlier by this laboratory (9) 
using a n  adaptation of the method of Pirani et al (19). 
Periarterial collections of lymphocytes were graded on  a 
scale from 0 to 4+. 
Statistical Analysis. T h e  MIDAS software package 
(20) developed by the Statistical Research Laboratory of 
the University of Michigan was used within the MTS 
system on the IBM 360/67 computer. Least squares regres- 
sion analysis was performed as described by Draper and 
Smith (21). Analysis of variance used to analyze the data 
derived from groups containing unequal numbers of mice 
(22) was calculated using the BMDX64 program (23), re- 
vised by the Statistical Research Laboratory of the Univer- 
sity of Michigan for use on the M T S  system. The P value 
was set a t  0.05. If the attained significance level was less 
than 0.05, the hypothesis under consideration was rejected. 
A descriptive statistical modelt was derived to eval- 
uate titered ANA data. This  additive model permitted 
evaluation of the effects of sex, type of treatment, duration 
of treatment, and interactions between these parameters 
o n  ANA titers. Based upon these calculations, predicted 
mean ANA titers were derived for each group of mice and 
compared with the experimental results. 
RESULTS 
ANA Fluc tua t ion  in Young NZB/NZW Mice. 
T i t e r e d  ANA tests were performed using sera col- 
lected f r o m  12 y o u n g  unt rea ted  mice ( T a b l e  1). No 
animals were  consistently ANA-posi t ive or -negative. 
A large number of positive tests were unexpectedly 
*I00 ml of toluene containing 4.0 g PPO (2,5-diphenyloxazole) 
and 0.1 g POPOP (1,4-bis-[2-(5-phenyloxazolyl)]-henzene). 
thitially, least squares regression techniques (21) confirmed that 
ANA titers did not increase consistently in individual mice as 
a function of age. Therefore, in subsequent calculations em- 
ploying analysis of variance, age was not included as a variable 
that might influence titers. T h e  usual distributional assump- 
tions on the error term were not satisfied. The following addi- 
tive model was constructed, subject to the usual zero-summa- 
bility constraints of the 3-way fixed effects analysis of variance 
(22): yr,*, = P + a6 + B, + v t  + ~ 4 , ‘ ~  + Ytt‘” + ~ , t ( * ’  +
y c J x  f e6,km, where Y , , ~ .  = ANA titer of the mth mouse at 
time k in the ith and jth treatment group, and e,,rm is the 
error term. Least squares estimates (21) of the above para- 
meters were obtained, and parameters were eliminated when 
the sums of squares for the effect were small compared to the 
total sum of squares. T h e  model finally considered was: y,,&” 
= P + ai + PI + viCu + eotm. 
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found in sera from young male mice compared to 
those from female mice. 
ANA Reproducibility. Aliquots of pooled ANA- 
positive mouse serum tested on 6 successive days gave 
consistently reproducible ANA titers at the same end 
point. 
Incidence of Positive ANA. The  incidence of 
positive tests in female control mice increased from 25% 
to lOOyo during the 52-week observation period, and 
fluctuation between positive and negative tests rarely 
occurred in individual animals in this group. Twenty- 
five percent of cyclophosphamide-treated female mice 
were ANA-positive at the beginning of this study. 
After 24 weeks of treatment the incidence of positive 
tests was 85y0; after 52 weeks ANA were detected in 
10 surviving treated female mice. Variability between 
positive and negative tests occurred in 7 of 10 high- 
dose treated female animals. In  male control mice, 
10 of 20 sera collected at the beginning of the study 
contained ANA. This unexpected finding (24) re- 
flected the early, transient appearance of ANA in 
young male NZB/NZW mice in our colony (Table 
1). The  incidence of positive tests for ANA increased 
from 45y0 at 8 weeks to 92Y0 at 52 weeks in male 
control mice. Fluctuation between positive and nega- 
tive tests occurred in 9 of 20 mice in this group. High- 
dose and low-dose cyclophosphamide therapy did not 
prevent the appearance of positive tests for ANA in 
male mice. In 6 of 10 high-dose male mice, fluctuation 
between positive and negative tests was noted. 
ANA Titers. Median titers of positive ANA 
tests and ranges within each group of control and 
treated mice are listed in Table 3. Sequential median 
titers in ANA-positive female control mice increased 
from 5 to 9 over a period of 52 weeks. Fluctuating 
titers were observed commonly in individual un- 
treated female mice. Only 5 of 16 female control mice 
surviving to the twenty-fourth week of this study had 
steadily increasing ti ters. High-dose therapy did not 
consistently suppress ANA titers in female mice. 
Median titers increased from 1 to 7 in female mice 
treated with cyclophosphamide (8 mg/kg/day) for 52 
weeks. Sequential titers showed great variation in 9 
of 10 high-dose female mice that developed ANA. In  
10 female mice treated with low-dose cyclophospha- 
mide (1 mg/kg/day), median titers increased from 5 
to 7 during the course of this study. Steadily increas- 
ing titers were observed in 7 of 10 low-dose female 
mice. Median ANA titers in untreated male mice rose 
from 3 at 0 weeks to 7 at 52 weeks. Fourteen male 
Table 3. Positive Titered Tests for A N A  in 80 
Cyclophosphamide-treated and Control NZB/NZW Mice  
Treatment Period (wk) 









1 (1-3)* 5 (3-7) 3 (1-9) 7 (1-9) 
131 [41 PI 
5 (5) 5 (3-11) 7 (1-11) 7 (7) 
[51 [61 Pl 
5 (3-7) 5 (1-9) 5 (1-11) 9 (5-1 1) 
[51 [61 P I  
3 (3) 3 (1-3) 1 (1-5) 5 (1-7) - 
[21 [21 [51 
[41 [51 [71 
[31 [41 [71 
Low dose 3 (3-5) 3 (1-5) 5 (3-7) 9 (3-11) 
Controls 3 (3-7) 5 (1-7) 3 (1-9) 7 (3-11) 
*Median (range). Values are expressed as highest tube number 
(l-logl of serum dilution) giving a positive test for heterogen- 
eous ANA determined by an indirect immunofluorescent tech- 
nique. Brackets enclose predicted cell means derived by least 
squares analysis (22) and rounded to the nearest integer. 
control mice had marked fluctuations in individual 
ANA titers. As a group, male mice treated with cycle 
phosphamide (8 mg/kg/day) had the lowest median 
ANA titers observed in this study. Consistent suppres- 
sion below comparable control values was evident 
throughout the first year of high-dose treatment. High- 
dose treated male mice demonstrated great variability 
of ANA titers. Median titers increased progressively 
from 3 to 9 in low-dose treated male mice, a fact sug- 
gesting that cyclophosphamide (1 mg/kg/day) may 
have augmented the autoantibody response in  this 
group of animals. 
Based on the descriptive statistical model de- 
scribed in Materials and Methods, predicted mean 
ANA titers at 8, 24, and 52 weeks were obtained by 
least squares analysis (21). These values are listed in 
Table 3. The  predicted cell means suggested that 
mean ANA titers within each group of control and 
treated mice were expected to increase during the 52- 
week observation period. It was anticipated that titers 
in male control and treated mice should be lower 
than titers in female mice at each bleeding point. 
Mean ANA titers in high-dose treated mice were ex- 
pected to be lower than titers in  control mice of the 
same sex. Based upon the use of derived cell means, 
it was anticipated that these trends would be repro- 
duced if this experiment were to be repeated. 
In  control and low-dose treated mice, individual 
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Table 4. Variable Patterns of Nuclear Fluorescence in 
Dilutions of ANA-positive Sera from 
Cyclophosphamide-treated and Control NZB/NZW Mice 
Treatment Period (wks) 
0 8 24 52 
Females and males 
Treated 
High dose 1 /6* 1 /7 4/9 4/14 
Low dose 3/5 6/11 14/19 5/10 
Controls 7/15 12/25 20/27 8/15 
*Number of sera with varying ANA patterns in serial dilutions/ 
total number of positive tests with titers > 1:l. 
samples of serum produced patterns of nuclear fluores- 
cence that changed as each subsequent dilution of the 
same sample was tested for ANA. Undiluted serum 
from those animals usually yielded a homogeneous 
or mixed pattern. As each sample of serum was tested 
after dilution a mixed or rim pattern often emerged. 
The incidence of changing patterns is shown in Table 
4. Variable patterns were found in sera collected from 
47 of 82 control mice and in 28 of 45 sera from low- 
dose treated mice of both sexes. High-dose cyclophos- 
phqmide therapy was commonly associated with the 
production of either homogeneous or rim patterns in 
titered sera. In  these samples, the initial rim or homo- 
geneous pattern produced by undiluted serum usually 
persisted in serial dilutions of the same sample of 
serum. Patterns varied in only 10 of 36 ANA-positive 
serum samples obtained from high-dose treated female 
and male mice. 
Anti-DNA. Mean anti-DNA values, expressed 
as percent of DNA bound to mouse serum measured 
at 0, 8, 24, and 52 weeks, are listed in Table 5. Before 
treatment, the range of mean DNA binding values in 
each group of mice was 14% to 18%. I n  the first 24 
weeks of the study, mean anti-DNA in female control 
mice increased from 14% to 28%. T w o  ANA-positive 
mice in this group failed to demonstrate an increase 
in anti-DNA levels during the first year of observation. 
High-dose cyclophosphamide therapy blunted the ex- 
pected age-dependent increase of DNA antibodies in 
female mice. After 24 weeks of treatment, female mice 
in this treatment group had a mean anti-DNA value 
of 19%, compared to 28% in  female control mice. In  
low-dose female mice, mean DNA-binding values in- 
creased from 15% to 55% during 52 weeks of treat- 
ment. One female mouse in this group produced sera 
with the highest anti-DNA level recorded in this study 
(82% at 52 weeks). 
In  untreated male mice, anti-DNA increased 
Table 5. Mean Anti-DNA in 80 
Cyclophosphamide-treated and Control Mice 
Treatment Period (wks) 
0 8 24 52 
Females 
Treated 
High dose 16 t 1 (8)* 14 f 2 (9) 19 -+ 1 (10) 15 f 1 (8) 
Lowdose 15 -+ 1(9) 23 f 3(10) 31 t 5(7) 55 (2) 
Controls 14 -+ 2 (13) 21 f 2 (20) 28 f 3 (13) 19 -C- 5 (3) 
Treated 
Males 
High dose 16 -+ 1 (8) 12 f 1 (10) 17 t 2 (6) 16 t 1 (6) 
Low dose 18 t 2 (7) 19 -+ 2 (9) 21 t 2 (9) 21 -+ 3 (8) 
Controls 15 -+ 1 (10) 15 f 1 (17) 26 * 3 (14) 25 t 3 (15) 
*Mean * SE. Values are expressed as percent of DNA bound. 
DNA binding was determined by a modification of the Farr 
Technique. Parentheses enclose number of mice tested a t  each 
time point. 
steadily from a mean pretreatment value of 15% to 
26y0 after 24 weeks of observation. Nine of 15 male 
control mice tested after 52 weeks continued to pro- 
duce DNA antibodies in excess of pretreatment values. 
An unexpected finding was the similarity between 
mean DNA binding values in male control NZB/ 
NZW mice compared to values in femare control mice 
after 24 weeks. DNA binding did not increase in male 
mice receiving high-dose cyclophosphamide. Mean 
values measured before treatment and after 52 weeks 
of treatment were the same (16y0). At 24 and 52 
weeks, mean anti-DNA in high-dose treated male mice 
was appreciably lower than anti-DNA in comparable 
control animals. Anti-DNA in low-dose treated male 
mice resembled values in male control mice. 
Data were evaluated by analysis of variance+ 
(22) to determine the effects of sex, therapy, and dura- 
tion of treatment on anti-DNA levels. These three fac- 
tors were significant a t  0.05. It was concluded that 
DNA binding increased significantly in all groups of 
control and low-dose treated mice during the first 24 
weeks of this study. Therapy with cyclophosphamide 
(8 mg/kg/day) was associated with significant depres- 
sion of anti-DNA in female and male NZB/NZW 
mice. 
Renal Histology. Table 6 lists mean values of 
glomerular lesions and vascular abnormalities observed 
*First, pretreatment values in treated and control mice were 
compared. Mean anti-DNA values in each group were similar 
at the beginning of the study (F statistic for each effect < 1.0; 
P < 0.05). Three-way analysis of variance was then employed 
to analyze anti-DNA data using the fixed effects model: yljin 
- p + a( + pi + rlr + eiik,,,, where yIlrn = anti-DNA level 
and vr = duration of treatment. 
- 
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Table 6. Renal Lesions in Cyclophosphamide-treated 
and Control NZB/NZW Mice 
Glomerular Periarterial 
Lesions Lymphocytes Arteritis 
Females 
Treated 
High dose 18 + 3* I (0-2)t 0/10$ 
2/ 10 
1/17 
Low dose 43 * 4 3 (2-4) 
Controls 44 c 3 2 (0-4) 
Males 
Treated 
High dose 23 * 3 0 (0-2) 0/10 
Low dose 46 & 4 3 (1-4) 
Controls 41 -+. 3 2 (0-4) 
6/9 
5/15 
*Mean number of histologic abnormalities counted in 20 glom- 
tMedian (range). Periarterial lymphocyte collections were scored 
$Number of kidneys with arteritis/number of kidneys examined. 
eruli f SE. 
on a scale of 0 to 4+. 
in kidneys from 71 cyclophosphamide-treated and con- 
trol NZB/NZW mice. Extensive glomerular damage 
was found in mice injected with saline or with cyclo- 
phosphamide, 1 mg/kg/day. Glomerular lesions were 
reduced significantly in mice treated with cyclophos- 
phamide, 8 mg/kg/day. Two-way analysis of variance 
(22) showed that the reduced numbers of glomerular 
lesions in high-dose treated mice, compared to control 
and low-dose treated mice, were significant at 0.01. 
This finding was in accord with the work of other 
investigators (3). The massive collections of round cells 
that usually surround renal arteries in old hybrid New 
Zealand mice were markedly reduced in high-dose 
treated animals. Necrotizing arteritis was present in 
kidney tissue from 19% of control and 42y0 of low- 
dose mice of both sexes. This vascular lesion was not 
found in renal tissue from 20 high-dose treated mice. 
DISCUSSION 
This report describes serial assays of auto- 
immune responsiveness in 80 cyclophosphamide- 
treated and control NZB/NZW mice followed for a 
period of 1 year. In  contrast to other investigations 
of autoantibody production in NZB/NZW mice (3,4), 
this study utilized sera obtained from serial bleedings 
of individual animals. Its procedure allowed the in- 
vestigators to detect the varying presence of ANA in 
certain control and treated mice. A separate study 
provided new information showing fluctuation be- 
tween positive and negative ANA tests and varying 
ANA titers in 5-week-old NZB/NZW mice. A new 
descriptive statistical model was derived to evaluate 
the influences of sex, type of therapy, and duration 
of therapy on titered ANA values. This study per- 
mitted comparison of ANA titers with anti-DNA as a 
useful index of cyclophosphamide-induced suppression 
of autoimmune disease in hybrid New Zealand mice. 
Heterogeneous ANA appeared to “resist” cyclophos- 
phamide therapy, whereas anti-DNA levels were sup- 
pressed consistently in high-dose treated animals. 
Finally, this study contributed new evidence suggest- 
ing that prolonged administration of low-dose cyclo- 
phosphamide paradoxically accelerated autoimmune 
NZB/NZW disease. 
In  the course of this study it was discovered 
that hybrid mice of both sexes had an early period 
of ANA reactivity characterized by variable presence 
of autoantibodies. Day-to-day fluctuations between 
positive and negative tests and variable titers were 
observed in untreated animals of both sexes tested 
between 5 and 7 weeks of age (Table 1). The  cause 
of ANA variability in  these animals is not known, 
but inconsistent presence of ANA may reflect the tran- 
sient presence of an inciting antigen in young NZB/ 
NZW mice. Lambert and Dixon (1) demonstrated a 
transient nuclear antigen in serum from a single NZB/ 
NZW mouse bled at different times. On the other 
hand, it may be postulated that young NZB/NZW 
mice have circulating ANA of low antigen-binding 
affinity, and these ANA are demonstrated transiently 
using the indirect immunofluorescent test. Petty and 
Steward (25) reported that young hybrid New Zealand 
mice produced low-affinity antibodies to human serum 
transferrin; the affinity of these antibodies was in- 
creased in older mice. The  striking early variability 
of ANA may explain the unexpectedly large number 
of positive tests in pretreatment sera from young male 
NZB/NZW mice detected at a single point in time. 
In  these young animals, the incidence of ANA in male 
mice temporarily exceeded ANA incidence in female 
mice. In older mice, inconstant positive tests persisted 
in 4576 of control male mice and in 60% of high-dose 
treated male mice. Older untreated females developed 
ANA that were persistent. Although every male mouse 
in this study was ANA-positive on at least one occa- 
sion, the pronounced variability of ANA responses in 
control and high-dose males may have contributed to 
the decreased severity of their autoimmune disease. 
NZB/NZW mouse disease is characterized by 
spontaneous appearance of autoantibodies followed by 
deposition of antigen-antibody complexes in renal 
glomeruli. Elution studies have demonstrated the pres- 
ence of nuclear antigens and anti-DNA in glomerular 
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deposits (1). Therefore, anti-DNA has been implicated 
as a specific agent leading to the development of im- 
mune complex glomerulonephritis in these mice. T h e  
effectiveness of cyclophosphamide in treating renal 
disease in NZB/NZW mice may reflect the ability of 
this drug to suppress humoral antibody formation (4). 
Russell and coworkers (2) found that parenteral ther- 
apy with cyclophosphamide (1.8 mg/week) suppressed 
antibody levels in female NZB/NZW mice challenged 
with flagellar antigen. The  immunosuppressive dose 
of cyclophosphamide used in their study was equiva- 
lent to the high dose of cyclophosphamide adminis- 
tered to mice on a daily basis in the current series. 
High-dose cyclophosphamide treatment (8 mg/kg/day) 
effectively suppressed anti-DNA levels, renal glomer- 
ular lesions, and vasculi tis. Titered heterogeneous 
ANA levels were relatively resistant to immunosup- 
pressive therapy. Based on information gained from 
this study, it was concluded that serial measurements 
of anti-DNA are more valuable than titered ANA 
in  evaluating active autoimmune disease in NZB/ 
NZW mice. 
In  low-dose treated mice there was no serologic 
or histologic evidence that administration of cyclo- 
phosphamide (1 mg/kg/day) suppressed the forma- 
tion of autoantibodies. The  high DNA binding levels, 
abundant collections of periarterial lymphocytes, and 
increased incidence of arteritis in these animals pro- 
vided evidence that the low dose of cyclophosphamide 
used in  this study may have paradoxically accelerated 
autoimmune disease in NZB/NZW mice. Although 
the immune-stimulating properties of cytoxic drugs 
are not widely recognized, other investigators have 
reported that administration of these agents may stim- 
ulate humoral antibody formation in certain experi- 
mental animals. Chanmougan and Schwartz (26) noted 
that rabbits treated with the antimetabolite 6-mercap- 
topurine, 10 mg/kg/day for 7 days, developed hyper- 
trophy of the spleen and lymph nodes. If bovine y- 
globulin was injected while hyperplasia persisted, 
humoral antibody response was enhanced. In  another 
study a single injection of cylophosphamide, 0.5 mg, 
stimulated antihuman 7-globulin levels in mice (27). 
The  enhancing properties of low-dose cyclophospha- 
mide in this animal model of autoimmune disease are 
currently under further investigation in this labora- 
tory. 
This report has reemphasized the value of high- 
dose cyclophospliamide in treating the SLE-like disease 
of NZB/NZW mice. However, the encouraging results 
were tempered by the high incidence of neoplasia in 
mice receiving long-term therapy (6). Anti-DNA meas- 
urements predicted suppression of renal disease in 
these animals. The  titered ANA, which tended to 
fluctuate in early or mild disease, was less reliable as 
a parameter of response to immunosuppressive therapy. 
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